Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.
Human prostate-specific antigen (PSA) has been widely used as a serum marker for cancer of the prostate. The cell type-specific expression of PSA also makes it a potential tumor antigen for prostate cancer immunotherapy. Study of the immunological aspects of PSA within either normal or malignant prostate tissue has been hampered by the lack of a mouse model, because no PSA counterpart has been identified in mice. Using a 14-kb genomic DNA region that encompasses the entire human PSA gene and adjacent flanking sequences, we generated a series of human PSA transgenic mice. In the six independent lines of transgenic mice generated, the expression of the human PSA transgene, driven by its own cis-acting regulatory elements, is specifically targeted to the prostate. Tissue distribution analysis demonstrated that PSA transgene expression closely follows the human expression pattern. Immunohistochemical analysis of the prostate tissue also showed that the expression of the PSA transgene is confined to the ductal epithelial cells. Despite expressing PSA as a self-antigen in the prostate, these transgenic mice were able to mount a cytotoxic immune response against PSA expressed by tumor cells, indicating that expression of the transgene has not resulted in complete nonresponsiveness. This transgenic mouse model will provide a well defined system to gain an insight into the mechanisms of nonresponsiveness to PSA, ultimately leading to strategies for immunotherapy of human prostate cancer using PSA as the target antigen.
Wei
C
C
Department of Microbiology and Immunology and the Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA.
Willis
R A
RA
Tilton
B R
BR
Looney
R J
RJ
Lord
E M
EM
Barth
R K
RK
Frelinger
J G
JG
D000818:Animals; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D017931:DNA Primers; D015316:Genetic Therapy / Q000379:methods; D005837:Genitalia, Male / Q000378:metabolism; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods; D007167:Immunotherapy / Q000379:methods; D008297:Male; D051379:Mice; D008822:Mice, Transgenic; D009928:Organ Specificity; D016133:Polymerase Chain Reaction; D017430:Prostate-Specific Antigen / Q000096:biosynthesis* / Q000235:genetics* / Q000276:immunology; D012333:RNA, Messenger / Q000096:biosynthesis; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000276:immunology; D012045:Regulatory Sequences, Nucleic Acid; D015183:Restriction Mapping; D014158:Transcription, Genetic; D014162:Transfection; D014407:Tumor Cells, Cultured
D017931:DNA Primers; D012333:RNA, Messenger; D011994:Recombinant Proteins; D017430:Prostate-Specific Antigen